Author
Listed:
- Di Dong
(Peking University Health Science Center)
- Zhe Zhou
(Peking University Health Science Center
Peking University)
- Minglu Zhu
(Peking University Health Science Center)
- Zhiyuan Hou
(Peking University Health Science Center)
- Mo Chen
(Peking University Health Science Center)
- Jingjing Gong
(Peking University Health Science Center)
- Xuyang Zhao
(Peking University Health Science Center)
- Aohui Yan
(Peking University Health Science Center)
- Hui Liang
(Peking University Health Science Center)
- Yuxin Yin
(Peking University Health Science Center
Peking University Shenzhen Hospital
Peking University Health Science Center)
Abstract
Pancreatic ductal adenocarcinoma (PDAC) poses a serious clinical challenge, demanding further exploration of its pathogenesis and therapeutic targets for metastasis, the main cause of mortality. Here, we identify STN1, a CST complex member crucial for maintaining telomere lengths and genome stability, as a key factor in promoting PDAC metastasis. Elevated STN1 levels correlate with poor patient survival, with oncogenic protein HOXB7 as an upstream transcription factor regulating STN1. Utilizing multiple PDAC experimental models, we discover STN1’s role in promoting metastasis by functioning as an upstream factor in epithelial-mesenchymal transition (EMT). Our mechanistic evidence suggests that during transcription, STN1 binds to structurally displaced single-stranded DNA flanking the R-loop, recruiting STAT3 to activate ZEB1 transcription independent of its known telomere maintenance function. Notably, STAT3 inhibitors show enhanced efficiency in restraining metastatic potential in STN1-overexpressed PDAC cells, offering a potential therapeutic avenue for targeting metastasis in STN1-overexpressed PDAC patients facing an unfavorable prognosis.
Suggested Citation
Di Dong & Zhe Zhou & Minglu Zhu & Zhiyuan Hou & Mo Chen & Jingjing Gong & Xuyang Zhao & Aohui Yan & Hui Liang & Yuxin Yin, 2025.
"STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer,"
Nature Communications, Nature, vol. 16(1), pages 1-16, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-63083-0
DOI: 10.1038/s41467-025-63083-0
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-63083-0. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.